HomeGeneticsConditionFibrochondrogenesis
Back to Condition
Fibrochondrogenesis
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Fibrochondrogenesis

Fibrochondrogenesis is a severe, rare disorder of bone growth characterized by short stature, distinctive facial features, and skeletal abnormalities that often lead to respiratory failure in infancy.

Overview

Fibrochondrogenesis is a very severe bone growth disorder. Affected infants typically have a narrow chest that prevents normal lung development, often resulting in stillbirth or death shortly after birth due to respiratory failure. However, some individuals have survived into childhood.

Symptoms

The condition is characterized by dwarfism and specific skeletal abnormalities, including:

  • Shortened long bones in the arms and legs that are unusually wide at the ends (dumbbell-shaped).
  • A narrow chest with short, wide ribs.
  • A round and prominent abdomen.
  • Flattened vertebrae (platyspondyly) with a pinched or pear-shaped appearance.
  • Underdeveloped hip (pelvic) bones.

Distinctive facial features include a flat-appearing midface, low-set ears, a small chin, and a nose with a flat bridge and nostrils that open to the front. Survivors may experience vision problems, such as severe nearsightedness (myopia) and clouding of the lens (cataracts), as well as sensorineural hearing loss.

Causes

Fibrochondrogenesis results from mutations in the COL11A1 (Type 1) or COL11A2 (Type 2) genes. These genes provide instructions for making components of type XI collagen, a molecule that provides structure and strength to cartilage and other connective tissues. Mutations impair the assembly of this collagen, weakening connective tissues and disrupting skeletal formation.

Inheritance

This condition is generally inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations. Parents of an affected individual typically carry one copy of the mutated gene without showing symptoms. In rare cases, COL11A2 mutations have been inherited in an autosomal dominant pattern, resulting from a new (de novo) mutation.

Frequently Asked Questions

Because the chest cavity is small, many infants develop respiratory insufficiency. Immediate measures include gentle positive‑pressure ventilation, high‑frequency oscillatory ventilation, or extracorporeal membrane oxygenation (ECMO) in specialized centers. Long‑term options are limited; most care focuses on comfort, palliative ventilation, and, when feasible, surgical rib expansion procedures, though outcomes are poor.
Yes. Molecular testing that identifies pathogenic variants in COL11A1 or COL11A2 confirms autosomal‑recessive inheritance. If both parents are carriers, each future pregnancy carries a 25 % risk of an affected child, a 50 % chance of being a carrier, and a 25 % chance of being unaffected and not a carrier. Prenatal carrier screening or pre‑implantation genetic diagnosis can be discussed with a genetics counselor.
Survivors need multidisciplinary care: regular ophthalmology for myopia and cataracts, audiology for sensorineural hearing loss, orthopedic monitoring for hip dysplasia and spinal deformities, and respiratory physiotherapy to maximize lung function. Nutritional support is important because a rounded abdomen can reflect feeding difficulties. Developmental and speech therapy help address motor delays, and families should receive psychosocial counseling.
Prenatal ultrasound may show a narrow thorax, short long bones with dumbbell ends, and platyspondyly; if these findings are present, targeted fetal genetic testing (amniocentesis or chorionic villus sampling) for COL11A1 or COL11A2 mutations can confirm the diagnosis. After birth, clinical examination of the characteristic skeletal and facial features, radiographs of the skeleton, and molecular genetic testing are used to establish the diagnosis.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA